Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9441)
All Articles published online
|
Publishing Process of This Article
|
Oct 28, 2018 (publication date) through Nov 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhang YW, Hu WL, Cai Y, Zheng WF, Du Q, Kim JJ, Kao JY, Dai N, Si JM. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J Gastroenterol 2018; 24(40): 4596-4605 [PMID: 30386109 DOI: 10.3748/wjg.v24.i40.4596] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v24/i40/4596.htm |
| Number | Citing Articles |
| 1 |
Ayush Khangai, Batsaikhan Saruuljavkhlan, Dashdorj Azzaya, Boldbaatar Gantuya, Khasag Oyuntsetseg, Junko Akada, Takashi Matsumoto, Yoshio Yamaoka. Exploring Alternative Treatment Choices for Multidrug-Resistant Clinical Strains of Helicobacter pylori in Mongolia. Microorganisms 2023; 11(12): 2852 doi: 10.3390/microorganisms11122852
|
| 2 |
Jing Liu, Chao-Ran Ji, Yue-Yue Li, Chen Qiao, Jun-Nan Hu, Meng Wan, Min-Juan Lin, Bo-Shen Lin, Juan Wang, Jing Zha, Li-Xiang Li, Xiu-Li Zuo. Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study. Clinical and Translational Gastroenterology 2021; 12(8): e00391 doi: 10.14309/ctg.0000000000000391
|
| 3 |
Lifen Lu, Yujing Wang, Jun Ye, Yuehua Han, Guochun Lou, Yan Li, Huihui Yan, Qin Du. Quadruple therapy with vonoprazan 20 mg daily as a first‐line treatment for Helicobacter pylori infection: A single‐center, open‐label, noninferiority, randomized controlled trial. Helicobacter 2023; 28(1) doi: 10.1111/hel.12940
|
| 4 |
Kai Zhang, Yu Han, Fangming Gu, Zhaoxuan Gu, JiaYu Zhao, Jianguo Chen, Bowen Chen, Min Gao, Zhengyan Hou, Xiaoqi Yu, Tianyi Cai, Yafang Gao, Rui Hu, Jinyu Xie, Tianzhou Liu. Association between dietary zinc intake and Helicobacter pylori seropositivity in US adults: National Health and Nutrition Examination Survey. Frontiers in Nutrition 2023; 10 doi: 10.3389/fnut.2023.1243908
|
| 5 |
Yaoyi Wu, Yujing Wang, Xiaochen Liu, Oulan Liao, Guochun Lou, Yan Li, Hao Wu, Qin Du, Jun Ye. Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment forHelicobacter pyloriinfection: a protocol of a single-centre, single-blind, randomised clinical trial in China. BMJ Open 2023; 13(7): e072670 doi: 10.1136/bmjopen-2023-072670
|
| 6 |
Jiali Zhang, Chunling Rong, Chenyang Yan, Jie Chen, Wenjun Yang, Lingyan Yu, Haibin Dai, Muhammad Shahzad Aslam. Risk factors of furazolidone-associated fever. PLOS ONE 2022; 17(4): e0266763 doi: 10.1371/journal.pone.0266763
|
| 7 |
Qiao‐Qiao Shao, Xue‐Chun Yu, Miao Yu, Jing Ma, Jun‐Bo Zhao, Lin Yuan, Ya‐Bin Qi, Ruo‐Bing Hu, Pei‐Ru Wei, Wei Xiao, Ling Lan, Bai‐Ling Jia, Lian‐Zhong Zhang, Song‐Ze Ding. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth‐containing quadruple therapy for Helicobacter pylori eradication in central China: A single‐center, prospective, open‐label, randomized‐controlled trial. Helicobacter 2022; 27(2) doi: 10.1111/hel.12876
|
| 8 |
Jingshu Chi, Canxia Xu, Xiaoming Liu, Hao Wu, Xiaoran Xie, Peng Liu, Huan Li, Guiying Zhang, Meihua Xu, Chaomin Li, Chunlian Wang, Fengqian Song, Ming Yang, Jie Wu. A Comparison of Doxycycline and Amoxicillin Containing Quadruple Eradication Therapy for Treating Helicobacter pylori-Infected Duodenal Ulcers: A Multicenter, Opened, Randomized Controlled Trial in China. Pathogens 2022; 11(12): 1549 doi: 10.3390/pathogens11121549
|
| 9 |
Liem Thanh Nguyen, Vuong Ba Nguyen, Tu Viet Tran, Huy Quang Duong, Loan Thi Thuy Le, Mai Huynh Truc Phuong, Thang Nguyen. Efficacy of Helicobacter pylori Eradication Based on Rabeprazole–Bismuth–Tetracycline–Tinidazole Regimen in Vietnamese Patients with Duodenal Ulcers. Gastroenterology Insights 2022; 13(4): 365 doi: 10.3390/gastroent13040036
|
| 10 |
Tian-Lian Yan, Jian-Guo Gao, Jing-Hua Wang, Dan Chen, Chao Lu, Cheng-Fu Xu. Current status of <i>Helicobacter pylori</i> eradication and risk factors for eradication failure. World Journal of Gastroenterology 2020; 26(32): 4846-4856 doi: 10.3748/wjg.v26.i32.4846
|
| 11 |
Jing Yu, Yiming Lv, Peng Yang, Yizhou Jiang, Xiangrong Qin, Xiaoyong Wang. Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-03002-z
|
| 12 |
Chao Ran Ji, Jing Liu, Yue Yue Li, Chen Qiao, Jun Yan Qu, Jun Nan Hu, Min Juan Lin, Rui Ji, Li Xiang Li, Xiu Li Zuo, Yan Qing Li. Susceptibility‐guided quadruple therapy is not superior to medication history‐guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial. Journal of Digestive Diseases 2020; 21(10): 549 doi: 10.1111/1751-2980.12934
|
| 13 |
Dina A. Gawad, Mai M. Elnaggar, Tarek S. Belal. Multi-analyte HPLC–DAD Method for Concurrent Analysis of Six Antimicrobials and Three Proton Pump Inhibitors Frequently used in Management of Helicobacter pylori Infection: Application to Simulated Intestinal Fluid Samples. Chromatographia 2022; 85(7): 617 doi: 10.1007/s10337-022-04168-6
|
| 14 |
Yan Zhou, Zishao Zhong, Shengjuan Hu, Jing Wang, Yanhong Deng, Ximei Li, Xianmei Chen, Xue Li, Yuanyuan Tang, Xiaofei Li, Qian Hao, Jun Liu, Tian Sang, Yang Bo, Feihu Bai.
A Survey of
Helicobacter pylori
Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China
. Antimicrobial Agents and Chemotherapy 2022; 66(6) doi: 10.1128/aac.02188-21
|
| 15 |
Weiwei Wang, Liying Qiao, Weiqi Dong, Jing Ren, Xiaotian Chang, Siyan Zhan, Peng Du, Yunfeng Xi, Shengfeng Wang. Differences in the Association Between Modifiable Lifestyle Factors and Gastric Precancerous Lesions Among Mongolians and Han Chinese. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.798829
|
| 16 |
Shu‐yan Zeng, Juan Wang, Jing Liu, Min‐Juan Lin, Bo‐Shen Lin, Yu‐Ming Ding, Qing‐Zhou Kong, Wen‐Lin Zhang, Miao Duan, Zhong‐Xue Han, Yue‐yue Li, Xiu‐Li Zuo, Yan‐Qing Li. Efficacy and safety of a 14‐day modified concomitant therapy for refractory Helicobacter pylori infection: a pilot study. Journal of Gastroenterology and Hepatology 2023; 38(12): 2097 doi: 10.1111/jgh.16348
|
| 17 |
Sotirios Georgopoulos, Vasilios Papastergiou. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opinion on Pharmacotherapy 2021; 22(6): 729 doi: 10.1080/14656566.2020.1845649
|
| 18 |
Brian White, Maria Winte, Joshua DeSipio, Sangita Phadtare. Clinical Factors Implicated in Antibiotic Resistance in Helicobacter pylori Patients. Microorganisms 2022; 10(2): 322 doi: 10.3390/microorganisms10020322
|
| 19 |
Mayuna Srisuphanunt, Polrat Wilairatana, Nateelak Kooltheat, Thitinat Duangchan, Gerd Katzenmeier, Joan B. Rose. Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies for Helicobacter pylori Infections. Tropical Medicine and Infectious Disease 2023; 8(3): 163 doi: 10.3390/tropicalmed8030163
|
| 20 |
RiHui Deng, LiYan Liu, WeiKe Xie, Weiguo Lu, Zhihui Liu, Yang Wang. Prevalence of Helicobacter pylori Antibiotic Resistance in Patients Enrolled in Guangzhou, China. Infection and Drug Resistance 2023; : 5033 doi: 10.2147/IDR.S418482
|
| 21 |
Elena Resina, Javier P. Gisbert. Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection. Antibiotics 2021; 10(9): 1028 doi: 10.3390/antibiotics10091028
|
| 22 |
Si‐Yu Li, Jiang Li, Xin‐Hong Dong, Gui‐Gen Teng, Wei Zhang, Hong Cheng, Wen Gao, Yun Dai, Xiao‐He Zhang, Wei‐Hong Wang. The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing. Helicobacter 2021; 26(4) doi: 10.1111/hel.12804
|
| 23 |
Dmitry S. Bordin, Irina N. Voynovan, Aiman S. Sarsenbaeva, Oleg V. Zaytsev, Rustam A. Abdulkhakov, Natalia V. Bakulina, Igor G. Bakulin, Marina F. Osipenko, Maria A. Livzan, Sergei A. Alekseenko. Effectiveness of empirical <i>Helicobacter pylori</i> eradication therapy with furazolidone in Russia: results from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg). Terapevticheskii arkhiv 2023; 95(2): 120 doi: 10.26442/00403660.2023.02.202107
|
| 24 |
Ying Ying Han, Ji Yan Li, Jia Lun Guan, Mei Liu, Pei Yuan Li. Application of furazolidone in Helicobacter pylori infection eradication. Journal of Digestive Diseases 2024; 25(3): 148 doi: 10.1111/1751-2980.13265
|
| 25 |
Jinliang Xie, Jianxiang Peng, Dingwei Liu, Rong Zeng, Jiayu Qiu, Liting Shen, Xiaomin Gong, Dongsheng Liu, Yong Xie. Treatment failure is a key factor in the development of Helicobacter pylori resistance. Helicobacter 2024; 29(3) doi: 10.1111/hel.13091
|
| 26 |
Erick A. Argueta, Steven F. Moss. Treatment of Helicobacter pylori. Current Opinion in Gastroenterology 2019; 35(6): 544 doi: 10.1097/MOG.0000000000000578
|